We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antifungal Drug May Kill Cancer Cells

By Biotechdaily staff writers
Posted on 05 Jul 2005
A medication that has been used for about 40 years for the treatment of skin fungus has been shown to be a potential treatment for cancer, according to a team of international researchers.

The agent, called griseofulvin, has been found to suppress the growth of cancer cells in the laboratory. More...
The findings of the study was published in the June 30, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences. The study was a collaboration between scientists at the University of California, Santa Barbara (UCSB; USA) and the School of Biosciences and Bioengineering of the Indian Institute of Technology Bombay.

"The drug has remarkably few side effects and has been used for a long time,” said Dr. Leslie Wilson, professor of biochemistry and pharmacology at UCSB. Griseofulvin is administered orally, and has been used for years to treat ringworm and other fungal skin infections.

"We discovered that it has the ability to inhibit the growth of cancer cells, in a manner that is similar to much more powerful anticancer drugs such as taxol and vinblastine,” said Dr. Wilson. "Although the anti-cancer activity is weak, it is already approved for human use and could be used along with more powerful anticancer agents as an adjuvant in cancer chemotherapy.”

The authors discovered that the drug suppresses the proliferation of cancer cells by affecting mitosis, or cell division, and mitotic spindle microtubule function. They concluded in their report, "A mild suppression of microtubule dynamics by griseofulvin in tumor cells, combined with the effects of more powerful drugs working through other mechanisms, might provide a therapeutic advantage for treatment of certain tumors.”





Related Links:
University of California, Santa Barbara
Indian Institute of Technology Bombay

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.